• Geron published early real-world community oncology data on RYTELO (imetelstat) use in lower-risk MDS anemia patients.
• In 24 evaluable patients, median hemoglobin rose 2.3-2.7 g/dL, with median peak 9.0-9.3 g/dL.
• Sensitivity analysis excluding labs within 14 days of transfusion showed a 2.5 g/dL median rise, with median peak 8.9-9.1 g/dL.
• Chart-captured ≥8-week transfusion-free intervals were seen in 73.3%, with incomplete documentation flagged as a limitation.
• Early grade 3-4 cytopenias were reported; cytopenias drove discontinuation in 20% of patients, prompting dose holds or reductions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Geron Corporation published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein.